Graft-versus-Host Disease Nutrition
Graft-versus-host disease (GVHD) is a complication of allogeneic hematopoietic stem cell transplantation in which donor immune cells attack the recipient's tissues. When it involves the gastrointestinal tract, it causes diarrhoea, abdominal pain, nausea, and mucosal injury that severely impair intake and absorption, making nutrition a central element of supportive care for affected patients.
Definition
GVHD nutrition is the clinical nutrition care of patients with graft-versus-host disease, especially gastrointestinal GVHD, in which donor-derived immune injury to the gut and other organs causes malabsorption, high-volume diarrhoea, and reduced intake that threaten nutritional status after allogeneic transplantation.
Scope
The topic covers gastrointestinal GVHD and its nutritional consequences, the acute and chronic forms relevant to nutrition, and the role of nutritional assessment and support in this complication. It is a reference overview and does not provide immunosuppressive regimens, dietary advancement protocols, or individualized nutrition prescriptions.
Core questions
- How does gastrointestinal graft-versus-host disease impair nutrition?
- Why are malabsorption and high-output diarrhoea central nutritional problems in gut GVHD?
- How do acute and chronic GVHD differ in their nutritional implications?
Key concepts
- Acute and chronic graft-versus-host disease
- Gastrointestinal GVHD
- Secretory and high-output diarrhoea
- Malabsorption and protein loss
- Oral, enteral, and parenteral support in GVHD
Mechanisms
In GVHD, donor T cells recognize host tissues as foreign and mount an immune attack, with the gastrointestinal tract a principal target. Gut GVHD damages the intestinal epithelium, producing voluminous secretory diarrhoea, protein loss, malabsorption of nutrients, nausea, and anorexia. These effects impair both intake and the absorption of what is consumed, while ongoing inflammation and immunosuppressive treatment add metabolic and infectious stress, so that severe gastrointestinal GVHD frequently requires substantial nutritional support to maintain status during recovery.
Clinical relevance
Because gastrointestinal GVHD can cause profound malabsorption and intake loss, nutritional assessment and support are integral to the supportive management of affected transplant patients alongside immunosuppressive therapy. This entry describes the nutritional dimension of GVHD for educational reference; the staging, treatment, and any nutritional intervention are individualized and directed by the transplant team.
Epidemiology
GVHD is a common complication of allogeneic hematopoietic stem cell transplantation, occurring in a substantial proportion of recipients in acute or chronic forms despite prophylaxis. Gastrointestinal involvement is a frequent feature of acute GVHD and a major driver of its nutritional burden and morbidity.
Evidence & guidelines
The review by Zeiser and Blazar (2017) describes the biology, prevention, and therapy of acute GVHD, including its gastrointestinal manifestations, the EBMT supportive care report (Nava et al., 2020) addresses nutrition among the supportive needs of transplant patients, and ESPEN guidance (Arends et al., 2017) covers nutritional support relevant to the malabsorption and intake loss seen in gut GVHD.
Key figures
- Robert Zeiser
- Bruce Blazar
- Selim Corbacioglu
Related topics
Seminal works
- zeiser-2017-agvhd
- nava-2020-ebmt
Frequently asked questions
- Why does graft-versus-host disease cause nutritional problems?
- When GVHD attacks the gastrointestinal tract it damages the gut lining, producing heavy diarrhoea, protein loss, and malabsorption along with nausea and poor appetite, so patients can lose nutrients faster than they take them in.
- Does GVHD nutrition only matter in the acute phase?
- No. Acute gastrointestinal GVHD causes intense, short-term malabsorption and diarrhoea, while chronic GVHD can produce longer-lasting effects on intake and nutritional status; both have nutritional implications that are managed individually.